N. Kogut

发表

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

A. Nademanee, A. Krishnan, G. Somlo, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

A. Krishnan, T. Schultheiss, J. Wong, 2010, Clinical Cancer Research.

relapsed non-Hodgkin lymphoma by autologous stem cell transplantation in patients with poor-risk or combination with high-dose etoposide and cyclophosphamide followed A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2005, Blood.

Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.

J. Doroshow, L. Leong, G. Somlo, 2000, Gynecologic oncology.

Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent

A. Nademanee, A. Krishnan, Shan Yuan, 2013, Transfusion.

Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports

G. Danovitch, S. Bunnapradist, N. Kogut, 2017, Transplantation direct.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation

A. Nademanee, J. Fridey, L. Weiss, 2007, Transfusion.

A phase II trial 90y-ibritumomab tiuxetan in combination with reduced intensity regimen of fludarabine (flu) and melphalan (mel) followed by allo-HCT in patients with refractory B-cell lymphoma.

A. Nademanee, S. Forman, A. Raubitschek, 2012 .

High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Non-Hodgkin's Lymphoma (NHL)

David D. Smith, A. Nademanee, A. Krishnan, 2017 .

Non-Hodgkins Lymphoma (NHL) by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Combination with High-Dose Etoposide and Cyclophosphamide Followed A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome

Y. Yen, J. Doroshow, L. Leong, 2001, British Journal of Cancer.

369: Reduced-intensity stem cell transplantation for high-risk acute lymphoblastic leukemia

S. Forman, D. Snyder, P. Parker, 2007 .

Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.

J. Doroshow, L. Leong, G. Somlo, 1999, Gynecologic oncology.

True histiocytic malignancy associated with a malignant teratoma in a patient with 46XY gonadal dysgenesis.

H. Rappaport, J. K. Cove, N. Kogut, 1992, The American journal of surgical pathology.

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.

Y. Yen, J. Doroshow, L. Leong, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.

A. Nademanee, S. Forman, K. Gaal, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control

A. Nademanee, S. Forman, D. Senitzer, 2011, Leukemia & lymphoma.

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.

David D. Smith, A. Krishnan, J. Zaia, 2005, Blood.

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

A. Nademanee, A. Krishnan, G. Somlo, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extramedullary relapse following reduced intensity allogeneic hematopoietic cell transplant for adult acute myelogenous leukemia

S. Forman, N. Kogut, Sandra H. Thomas, 2013, Leukemia & lymphoma.

Autologous stem cell transplantation for HIV-associated lymphoma.

A. Nademanee, A. Krishnan, J. Zaia, 2001, Blood.

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

A. Krishnan, S. Forman, D. Senitzer, 2010, Blood.

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

M. Angelopoulou, G. Somlo, S. Forman, 2004, Bone Marrow Transplantation.

A comparison of single-dose and fractionated total-body irradiation on the development of pneumonitis following bone marrow transplantation.

A. Kagan, N. Kogut, M. Tome, 1996, International journal of radiation oncology, biology, physics.

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome

M. Slovak, S. Forman, R. Bhatia, 2007, Bone Marrow Transplantation.

Conditional Survival and Cause-specific Mortality after Autologous Hematopoietic Cell Transplantation for Hematological Malignancies

A. Nademanee, A. Krishnan, S. Bhatia, 2012, Leukemia.

Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.

M. Slovak, S. Forman, D. Senitzer, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

A. Nademanee, S. Forman, J. Rosenthal, 2011, Annals of Hematology.

Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?

A. Nademanee, A. Krishnan, M. Slovak, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer

J. Doroshow, L. Leong, P. Frankel, 2002, British Journal of Cancer.

Tacrolimus and Sirolimus as GVHD Prophylaxis for Sibling Donor Hematopoietic Stem Cell Transplant (HCT) Using Three Conditioning Regimens; Fludarabine-Melphalan, FTBI-VP16, and Busulfan-Cyclophosphamide

S. Forman, D. Senitzer, D. Snyder, 2009 .

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

Y. Yen, J. Doroshow, L. Leong, 2004, Journal of Clinical Oncology.

HIV-associated lymphomas Durable remissions with autologous stem cell transplantation for high risk

David D. Smith, A. Krishnan, J. Zaia, 2013 .

Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Acute Lymphoblastic Leukemia: A Potential Therapeutic Approach for High Risk ALL Patients Not Eligible for Full Intensity Transplantation

M. Slovak, S. Forman, R. Spielberger, 2008 .

Feasibility and Efficacy of Mobilization of BCR/ABL- PBSC in CML Patients Receiving Imatinib.

M. Slovak, S. Forman, R. Bhatia, 2004 .

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

A. Krishnan, P. Frankel, G. Somlo, 2006, Bone Marrow Transplantation.

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

A. Nademanee, A. Krishnan, S. Forman, 2010 .

90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

A. Krishnan, T. Schultheiss, J. Wong, 2010, Clinical Cancer Research.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2007 .

Apheresis of Deceased Donors as a New Source of Mobilized Peripheral Blood Hematopoietic Stem Cells for Transplant Tolerance

B. Naini, E. Reed, J. Veale, 2022, Transplantation.

Autologous stem cell transplant (ASCT) for AIDS-related lymphoma (ARL)

A. Nademanee, A. Krishnan, J. Zaia, 2009, Infectious Agents and Cancer.